JP2010510317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510317A5 JP2010510317A5 JP2009538461A JP2009538461A JP2010510317A5 JP 2010510317 A5 JP2010510317 A5 JP 2010510317A5 JP 2009538461 A JP2009538461 A JP 2009538461A JP 2009538461 A JP2009538461 A JP 2009538461A JP 2010510317 A5 JP2010510317 A5 JP 2010510317A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- alkyl
- aryl
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 amino, substituted amino Chemical group 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 150000001602 bicycloalkyls Chemical group 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 5
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 5
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 5
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 5
- 125000001769 aryl amino group Chemical group 0.000 claims 5
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims 5
- 125000005241 heteroarylamino group Chemical group 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 125000005592 polycycloalkyl group Polymers 0.000 claims 5
- 125000006684 polyhaloalkyl group Polymers 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 5
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 4
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 4
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims 4
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 4
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 4
- 125000005095 alkynylaminocarbonyl group Chemical group 0.000 claims 4
- 239000003472 antidiabetic agent Substances 0.000 claims 4
- 239000003524 antilipemic agent Substances 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000036119 Frailty Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 239000000883 anti-obesity agent Substances 0.000 claims 2
- 229940125708 antidiabetic agent Drugs 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 229940030600 antihypertensive agent Drugs 0.000 claims 2
- 229940125710 antiobesity agent Drugs 0.000 claims 2
- 229940127218 antiplatelet drug Drugs 0.000 claims 2
- 239000002830 appetite depressant Substances 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 2
- 206010003549 asthenia Diseases 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 208000037824 growth disorder Diseases 0.000 claims 2
- 229940125699 infertility agent Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical group 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 1
- 125000004689 alkyl amino carbonyl alkyl group Chemical group 0.000 claims 1
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims 1
- 230000003262 anti-osteoporosis Effects 0.000 claims 1
- 229940124605 anti-osteoporosis drug Drugs 0.000 claims 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86020206P | 2006-11-20 | 2006-11-20 | |
| PCT/US2007/084927 WO2008064107A2 (en) | 2006-11-20 | 2007-11-16 | 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510317A JP2010510317A (ja) | 2010-04-02 |
| JP2010510317A5 true JP2010510317A5 (https=) | 2010-12-16 |
Family
ID=39283892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538461A Withdrawn JP2010510317A (ja) | 2006-11-20 | 2007-11-16 | ジペプチジルペプチダーゼｉｖの阻害剤としての７，８−ジヒドロ−１，６−ナフチリジン−５（６ｈ）−オンおよび関連二環式化合物、および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7723355B2 (https=) |
| EP (1) | EP2086975B1 (https=) |
| JP (1) | JP2010510317A (https=) |
| CN (1) | CN101595109B (https=) |
| AT (1) | ATE549334T1 (https=) |
| ES (1) | ES2382486T3 (https=) |
| NO (1) | NO20091938L (https=) |
| WO (1) | WO2008064107A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE521353T1 (de) * | 2000-10-23 | 2011-09-15 | Glaxosmithkline Llc | Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten |
| UY29440A1 (es) * | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| EP1865959A2 (en) * | 2005-03-25 | 2007-12-19 | Glaxo Group Limited | Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2308847B1 (en) | 2009-10-09 | 2014-04-02 | EMC microcollections GmbH | Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| US8477028B2 (en) * | 2010-09-24 | 2013-07-02 | T-Mobile Usa, Inc. | Misplaced device recovery |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104583197B (zh) * | 2012-08-24 | 2017-05-17 | 霍夫曼-拉罗奇有限公司 | 新型双环吡啶衍生物 |
| WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
| CN104548096B (zh) * | 2013-10-09 | 2019-09-10 | 深圳翰宇药业股份有限公司 | 一种含有glp-1类似物和dpp-4抑制剂的药物组合物及其制备方法 |
| US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| SMT202500271T1 (it) | 2020-07-02 | 2025-09-12 | Incyte Corp | Composti di urea triciclici come inibitori di v617f di jak2 |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900224B2 (en) * | 2002-07-31 | 2005-05-31 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
| EP1539709A1 (en) * | 2002-08-13 | 2005-06-15 | Warner-Lambert Company LLC | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| GB0413389D0 (en) * | 2004-06-16 | 2004-07-21 | Astrazeneca Ab | Chemical compounds |
| WO2006019965A2 (en) * | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| GB0420970D0 (en) * | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
| WO2006065842A2 (en) * | 2004-12-13 | 2006-06-22 | Synta Pharmaceuticals Corp. | 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof |
-
2007
- 2007-11-16 WO PCT/US2007/084927 patent/WO2008064107A2/en not_active Ceased
- 2007-11-16 ES ES07864519T patent/ES2382486T3/es active Active
- 2007-11-16 US US11/941,181 patent/US7723355B2/en active Active
- 2007-11-16 JP JP2009538461A patent/JP2010510317A/ja not_active Withdrawn
- 2007-11-16 EP EP07864519A patent/EP2086975B1/en active Active
- 2007-11-16 AT AT07864519T patent/ATE549334T1/de active
- 2007-11-16 CN CN2007800501380A patent/CN101595109B/zh not_active Expired - Fee Related
-
2009
- 2009-05-19 NO NO20091938A patent/NO20091938L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510317A5 (https=) | ||
| JP2011512352A5 (https=) | ||
| JP2007512370A5 (https=) | ||
| RU2317294C2 (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
| JP2011519374A5 (https=) | ||
| JP2013040219A5 (https=) | ||
| JP2008526869A5 (https=) | ||
| JP2021534124A5 (https=) | ||
| JP2011515398A5 (https=) | ||
| JP2011520792A5 (https=) | ||
| JP2012516871A5 (https=) | ||
| RU2008152763A (ru) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии | |
| RU2003117476A (ru) | Аминотиазолы и их применение в качестве антагонистов рецептора аденозина | |
| RU2005110061A (ru) | Замещенные пиперазины, (1,4)-диазепины и 2,5-диазабицикло(2,2,1)гептаны в качестве н1-и/или н3-антагонистов гистамина или обратных н3-антагонистов гистамина | |
| JP2013538235A5 (https=) | ||
| RU2017144495A (ru) | Противогельминтные депсипептидные соединения | |
| JP2007533741A5 (ja) | Ｂａｃｅ阻害剤として有用なピロリジン誘導体 | |
| JP2007517035A5 (https=) | ||
| JP2006524660A5 (https=) | ||
| JP2010510233A5 (https=) | ||
| JPWO2023099592A5 (https=) | ||
| JP2009532486A5 (https=) | ||
| JP2018509418A5 (https=) | ||
| JP2009502948A5 (https=) | ||
| AR052658A1 (es) | Inhibidores de dipeptidil-peptidasa iv basados en azolopirimidina |